Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

K Y Thong; R E J Ryder; M L Cull; C Walton; ABCD Nationwide Exenatide and Liraglutide Audit Contributors; Priya George

doi:10.1111/j.1464-5491.2011.03475.x

Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

K Y Thong, R E J Ryder, M L Cull, C Walton, ABCD Nationwide Exenatide and Liraglutide Audit Contributors, Priya George

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	690-692
Number of pages	3
Journal	Diabetic Medicine
Volume	29
Issue number	5
DOIs	https://doi.org/10.1111/j.1464-5491.2011.03475.x
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1464-5491.2011.03475.x

Cite this

Thong, K. Y., Ryder, R. E. J., Cull, M. L., Walton, C., ABCD Nationwide Exenatide and Liraglutide Audit Contributors, & George, P. (2012). Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabetic Medicine, 29(5), 690-692. https://doi.org/10.1111/j.1464-5491.2011.03475.x

@article{7e15f181fd804574818e33d740dae9a3,

title = "Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits",

author = "Thong, {K Y} and Ryder, {R E J} and Cull, {M L} and C Walton and {ABCD Nationwide Exenatide and Liraglutide Audit Contributors} and Priya George",

year = "2012",

doi = "10.1111/j.1464-5491.2011.03475.x",

language = "English",

volume = "29",

pages = "690--692",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell",

number = "5",

}

Thong, KY, Ryder, REJ, Cull, ML, Walton, C, ABCD Nationwide Exenatide and Liraglutide Audit Contributors & George, P 2012, 'Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits', Diabetic Medicine, vol. 29, no. 5, pp. 690-692. https://doi.org/10.1111/j.1464-5491.2011.03475.x

Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. / Thong, K Y; Ryder, R E J; Cull, M L et al.
In: Diabetic Medicine, Vol. 29, No. 5, 2012, p. 690-692.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

AU - Thong, K Y

AU - Ryder, R E J

AU - Cull, M L

AU - Walton, C

AU - ABCD Nationwide Exenatide and Liraglutide Audit Contributors

AU - George, Priya

PY - 2012

Y1 - 2012

U2 - 10.1111/j.1464-5491.2011.03475.x

DO - 10.1111/j.1464-5491.2011.03475.x

M3 - Letter

C2 - 21988449

SN - 0742-3071

VL - 29

SP - 690

EP - 692

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 5

ER -

Thong KY, Ryder REJ, Cull ML, Walton C, ABCD Nationwide Exenatide and Liraglutide Audit Contributors, George P. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabetic Medicine. 2012;29(5):690-692. doi: 10.1111/j.1464-5491.2011.03475.x